ABVX
Abivax S.A. NASDAQ$117.13
Pre-mkt
$124.34
+6.16%
Mkt Cap $7.7B
52w Low $5.59
77.9% of range
52w High $148.83
50d MA $117.01
200d MA $103.09
P/E (TTM)
-25.3x
EV/EBITDA
-31.3x
P/B
18.0x
Debt/Equity
0.1x
ROE
—
P/FCF
-51.2x
RSI (14)
—
ATR (14)
—
Beta
-0.10
50d MA
$117.01
200d MA
$103.09
Avg Volume
930.2K
About
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phas…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -1.07 | -1.22 | -13.8% | 115.42 | +0.6% | -4.5% | -4.1% | -5.1% | -11.2% | -12.1% | — |
| Sep 8, 2025 | AMC | -0.90 | -0.86 | +4.4% | 90.00 | -0.7% | -0.8% | -2.6% | -4.5% | -6.7% | -4.6% | — |
| Mar 24, 2025 | AMC | -0.68 | -1.55 | -128.0% | 7.37 | +2.3% | -0.4% | -3.8% | -7.5% | -12.8% | -15.2% | — |
| Nov 7, 2024 | AMC | -1.28 | -0.70 | +45.5% | 10.54 | -2.2% | -0.7% | +0.1% | -2.0% | -3.4% | -5.5% | — |
| Apr 2, 2024 | AMC | -0.91 | -1.94 | -112.7% | 14.04 | +1.1% | +6.4% | +6.4% | +5.8% | +7.5% | +6.1% | — |
| Jun 30, 2023 | AMC | — | -1.58 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2022 | AMC | -1.93 | -1.95 | -0.8% | — | — | — | — | — | — | — | — |
| Jun 30, 2022 | AMC | — | -1.84 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2021 | AMC | — | -1.68 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2021 | AMC | — | -1.34 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 | Barclays | Maintains | Overweight → Overweight | — | $115.42 | $116.16 | +0.6% | -4.5% | -4.1% | -5.1% | -11.2% | -12.1% |
| Feb 25 | BTIG | Maintains | Buy → Buy | — | $128.29 | $125.70 | -2.0% | -3.9% | -6.9% | -5.5% | -11.8% | -13.4% |
| Jan 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $115.49 | $118.62 | +2.7% | -0.9% | +2.2% | +3.6% | +8.2% | +1.1% |
| Jan 8 | BTIG | Maintains | Buy → Buy | — | $126.48 | $125.10 | -1.1% | -8.7% | -9.6% | -6.7% | -5.4% | -1.2% |
| Dec 16 | Citizens | Maintains | Market Outperform → Market Outperform | — | $117.91 | $113.00 | -4.2% | -5.9% | -6.0% | -3.6% | -2.5% | +17.6% |
| Oct 10 | Guggenheim | Maintains | Buy → Buy | — | $90.61 | $93.71 | +3.4% | +3.5% | +5.5% | +8.0% | +5.5% | +2.5% |
| Oct 7 | BTIG | Maintains | Buy → Buy | — | $86.67 | $87.32 | +0.8% | +0.4% | -0.2% | +4.5% | +8.2% | +10.3% |
| Sep 25 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $82.55 | $83.00 | +0.5% | -0.7% | +0.4% | +0.9% | +2.8% | -0.2% |
| Sep 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $85.96 | $83.00 | -3.4% | -2.3% | -0.1% | -4.3% | -5.8% | -3.1% |
| Sep 9 | BTIG | Maintains | Buy → Buy | — | $90.00 | $89.40 | -0.7% | -0.8% | -2.6% | -4.5% | -6.7% | -4.6% |
Data updated apr 26, 2026 9:26am
· Source: massive.com